From the Journals

COVID-19 antibody response not reduced with diabetes

Publish date: October 20, 2020

 

A version of this article originally appeared on Medscape.com.

Pages

Recommended Reading

Time to screen for liver disease in type 2 diabetes?
MDedge Family Medicine
PPIs associated with diabetes risk, but questions remain
MDedge Family Medicine
EMPEROR-Reduced: Empagliflozin’s HFrEF benefit holds steady on top of sacubitril/valsartan
MDedge Family Medicine
Choosing Wisely: 10 practices to stop—or adopt—to reduce overuse in health care
MDedge Family Medicine
Chronic, nonhealing leg ulcer
MDedge Family Medicine
T2D treatments create tension between glycemic and cardiovascular goals
MDedge Family Medicine
These images of diabetic retinopathy tell the story better
MDedge Family Medicine
Entresto halves renal events in preserved EF heart failure patients
MDedge Family Medicine
Substance in tears could be used for diabetes monitoring
MDedge Family Medicine
Recall widens for diabetes drug metformin
MDedge Family Medicine